Affibody Overview
- Founded
-
1998

- Status
-
Private
- Employees
-
113

- Latest Deal Type
-
Debt
- Latest Deal Amount
-
$21M
- Investors
-
3
Affibody General Information
Description
Operator of a private clinical-stage biopharma company intended to develop protein-based drugs. The company engages in the research and development of drugs and monoclonal antibodies through its therapeutic programs that target psoriasis and B-cell drove autoimmune diseases respectively, enabling doctors to get access to therapies that improve the lives of patients with serious diseases.
Contact Information
Website
affibody.se
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- Scheeles väg 2
- 171 65 Solna
- Sweden
+46 08-598 000 00
Affibody Timeline
Affibody Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Debt - General | 22-Dec-2022 | $21M | 00000 | Completed | Profitable | |
6. Secondary Transaction - Private | 01-Feb-2021 | 000.00 | Completed | Profitable | ||
5. Later Stage VC | 08-Mar-2018 | 000.00 | 000.00 | Completed | Profitable | |
4. Secondary Transaction - Private | 01-Jan-2014 | 000.00 | Completed | Profitable | ||
3. Later Stage VC | 30-Mar-2007 | 000.00 | 000.00 | Completed | Generating Revenue | |
2. Early Stage VC | 03-Oct-2001 | $28M | $28M | Completed | Startup | |
1. Early Stage VC | 30-Jun-2000 | Completed | Startup |
Affibody Patents
Affibody Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2020380524-A1 | New process of extracting protein | Pending | 08-Nov-2019 | 000000000 | |
CA-3160027-A1 | New process of extracting protein | Pending | 08-Nov-2019 | 000000000 | |
EP-4055027-A1 | New process of extracting protein | Pending | 08-Nov-2019 | 000000000 | |
US-20220411743-A1 | New process of extracting protein | Pending | 08-Nov-2019 | 000000000 | |
US-20220389066-A1 | Polypeptides | Pending | 05-Nov-2019 | C07K14/435 |
Affibody Executive Team (18)
Affibody Board Members (10)
Name | Representing | Role | Since |
---|---|---|---|
Anders Martin-Löf | Self | Board Member | 000 0000 |
Camilla Sønderby | Self | Board Member | 000 0000 |
Gillian Cannon Ph.D | Affibody | Board Member | 000 0000 |
Jakob Lindberg MD | Self | Board Member | 000 0000 |
Jonathan Knowles Ph.D | Self | Board Member | 000 0000 |
Affibody Signals
Affibody Investors (3)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Investor | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Ingvar Kamprad | Angel (individual) | Minority | 000 0000 | 000000 0 | |
Lage Jonason | Angel (individual) | Minority | 000 0000 | 000000 0 |
Affibody Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000 000000 | 29-Jun-2001 | 0000000000 | Other Healthcare Technology Systems |